Search results
Added:
6 months ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Added:
3 years ago
Heart failure is a major health concern in the US and is particularly problematic in the African-American community where the disease has an earlier onset and exhibits increased mortality, even with hospitalisation. Early onset is manifested primarily in middle-aged patients, where the rates of heart failure are higher than that with a higher mortality than in whites. Between the ages of 45 and…
View more
Added:
3 years ago
After a drought in viable new therapies for more than a decade, two new drugs for use in heart failure patients were approved by the US Food and Drug Administration (FDA) in 2015. These drugs represent two new classes of agents in the heart failure space: a combined angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan; brand name Entresto®, Novartis) and a sinoatrial node…
View more
Added:
10 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
…
View more
Added:
3 years ago
Abstract
Heart failure with preserved left ventricular ejection fraction (HF-PEF), sometimes named diastolic heart failure, is a common condition most frequently seen in the elderly and is associated with arterial hypertension and left ventricular (LV) hypertrophy. Symptoms are attributed to a stiff left ventricle with compensatory elevation of filling pressure and reduced ability to increase…
View more
Added:
7 months ago
Join the Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) and Dr Milton Packer (Baylor University Medical Center, US) for a thought-provoking discussion on the present and future of heart failure care at ESC Congress 2023.
In this unique exchange, Dr Packer shares his thoughts on heart failure guidelines and the '2023 Focused Update of the 2021 ESC Guidelines for the…
View more
Added:
1 year ago
Heart failure management: Where are we now?
Dip into the new heart failure data presented at ESC-HF Conference 2022. Learn more about the latest research and treatment options delivered by researchers driving the field.Short, accessibleExpert Interviewswill be available with select faculty focusing on the results, applicability, and impact on future research.
Join globally renown faculty as…
View more
Added:
3 years ago
Several cardiac biomarkers may aid in the diagnostic and prognostic evaluation of acute and chronic heart failure. In this article we discuss more novel and emerging applications of such established cardiac biomarkers in heart failure and review emerging data for several other promising markers.
Novel Applications of Established Cardiac Biomarkers—Natriuretic Peptides
B-type natriuretic peptide…
View more
Added:
1 year ago
In this video series, first presented at the ESC Congress 2022, held in Barcelona, Prof Ralph Stephan von Bardeleben, Prof Jose LuisZamorano, Dr Victoria Delgado, Prof DavideCapodanno and Dr SashaKoul discuss the diagnosis of low flow/low gradient aortic stenosis, which patients gain the most benefit from TAVI and how to avoid heart failure in aortic stenosis patients. Join this international…
View more
Added:
3 years ago
Chronic heart failure is common, disabling and deadly. It affects approximately five million people in the US and accounts for over one million hospitalizations annually.1 Despite continued improvements in heart failure therapy, mortality over five years is approximately 50%.2 This article summarizes significant recent developments in pharmacologic and device therapy for heart failure.
…
View more
« First